Scholarlink

<p>Dedifferentiated chondrosarcoma (dCS) is a rare, aggressive subtype of chondrosarcoma, characterized by an abrupt transition between a low-grade cartilaginous tumor and high-grade non-cartilaginous sarcoma. Treatment of dedifferentiated chondrosarcoma is limited by its high metastatic potential and poor response to chemotherapy and radiotherapy. Surgical resection remains the primary approach; however, recurrence and distant metastases substantially reduce survival rates. To provide a fundamental research resource, we aimed to establish a novel cell line of dCS. We successfully developed the NCC-dCS2-C1 cell line using surgically resected tumor tissue from a patient with dCS. This cell line harbors an <i>IDH1</i> mutation (p.R132S) and exhibits complex copy number variants. NCC-dCS2-C1 cells exhibited constant proliferation in monolayer culture, spheroid formation in low-attachment plates, and migration. High-throughput screening of 221 anticancer drugs using NCC-dCS2-C1 identified three candidates, ixazomib, pazopanib, and ponatinib, that demonstrated low IC<sub>50</sub> values, indicating their potential efficacy in treating dCS. We conclude that NCC-dCS2-C1 is a valuable tool for preclinical and basic research on dCS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Establishment and characterization of NCC-dCS2-C1: a novel patient-derived cell line of dedifferentiated chondrosarcoma

  • 期刊论文

  • 发表日期：

    2025年3月24日

查看全文
  • Shuhei Iwata,
  • Takuya Ono,
  • Rei Noguchi,
  • Julia Osaki,
  • Yuki Adachi,
  • Yomogi Shiota,
  • Suguru Fukushima,
  • Shogo Nishino,
  • Akihiko Yoshida,
  • Seiji Ohtori,
  • Akira Kawai,
  • Tadashi Kondo

摘要

Dedifferentiated chondrosarcoma (dCS) is a rare, aggressive subtype of chondrosarcoma, characterized by an abrupt transition between a low-grade cartilaginous tumor and high-grade non-cartilaginous sarcoma. Treatment of dedifferentiated chondrosarcoma is limited by its high metastatic potential and poor response to chemotherapy and radiotherapy. Surgical resection remains the primary approach; however, recurrence and distant metastases substantially reduce survival rates. To provide a fundamental research resource, we aimed to establish a novel cell line of dCS. We successfully developed the NCC-dCS2-C1 cell line using surgically resected tumor tissue from a patient with dCS. This cell line harbors an IDH1 mutation (p.R132S) and exhibits complex copy number variants. NCC-dCS2-C1 cells exhibited constant proliferation in monolayer culture, spheroid formation in low-attachment plates, and migration. High-throughput screening of 221 anticancer drugs using NCC-dCS2-C1 identified three candidates, ixazomib, pazopanib, and ponatinib, that demonstrated low IC50 values, indicating their potential efficacy in treating dCS. We conclude that NCC-dCS2-C1 is a valuable tool for preclinical and basic research on dCS.